Research has shown that glucagon stimulates gluconeogenesis through the liver lipolysis mediated by inositol triphosphate receptor 1 (INSP3R1), suggesting that INSP3R1 may be a new target for the treatment of type 2 diabetes (Perry et al., 2020). The gene discussed is ITPR1; the disease is type 2 diabetes mellitus.